Last reviewed · How we verify
T2026
At a glance
| Generic name | T2026 |
|---|---|
| Also known as | Absorption enhancer excipient |
| Sponsor | Sciwind Biosciences APAC CO Pty. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T2026 CI brief — competitive landscape report
- T2026 updates RSS · CI watch RSS
- Sciwind Biosciences APAC CO Pty. Ltd. portfolio CI